Portal de Periódicos da CAPES

Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity

1990; Elsevier BV; Volume: 39; Issue: 1 Linguagem: Inglês

10.1016/0006-2952(90)90664-7

1873-2968

Claude Linassier, Michel Pierre, Jean‐Bernard Le Pecq, Josiane Pierre,

Phytochemicals and Antioxidant Activities

Genistein has been shown to inhibit specifically in vitro the epidermal growth factor (EGF)-receptor tyrosine protein kinase activity (Akiyama et al., J Biol Chem262: 5592–5597, 1987). When the effects of genistein on NIH-3T3 cells were studied, a cytostatic effect was observed at low concentration ( 40μM). Genistein was able to block the mitogenic effect mediated by EGF on NIH-3T3 cells (ic50 = 12 μM) or by insulin (ic50 = 19 μM). Genistein was also able to block the mitogenic effect mediated by thrombin (IC50 = 20 μM) although the thrombin receptor does not involve a protein tyrosine kinase activity. Genistein at cytostatic concentration (<40 μM) did not prevent the induction of c-myc mRNA synthesis caused by the activation of EGF receptor by EGF. Therefore the cytostatic effect of genistein on NIH-3T3 cells did not appear to be mediated by EGF receptor tyrosine kinase inhibition. This hypothesis was also supported by the absence of effect of genistein on the EGF-stimulated phosphorylation of several proteins and particularly of a cytosolic 80 kD protein. The stimulation of S6 kinase activity of cells treated by EGF was prevented by genistein. The stimulation by EGF of in situ S6 phosphorylation was also prevented by genistein. In addition, S6 kinase extracted from cells treated by EGF was inhibited by genistein. These effects occur at similar doses and maximal inhibition of S6 kinase was obtained at about 15 μM.